From maria2657@comcast.net  Fri Feb 10 18:14:04 2006
Return-Path: <maria2657@comcast.net>
Received: from mx1.FreeBSD.org (mx1.freebsd.org [216.136.204.125])
	by hub.freebsd.org (Postfix) with ESMTP id 77D1C16A422
	for <freebsd-gnats-submit@freebsd.org>; Fri, 10 Feb 2006 18:14:04 +0000 (GMT)
	(envelope-from maria2657@comcast.net)
Received: from comcast.net (c-67-168-182-30.hsd1.wa.comcast.net [67.168.182.30])
	by mx1.FreeBSD.org (Postfix) with ESMTP id B32E643D45
	for <freebsd-gnats-submit@freebsd.org>; Fri, 10 Feb 2006 18:14:03 +0000 (GMT)
	(envelope-from maria2657@comcast.net)
Message-Id: <015401c62def$fe6826b0$f95ae0f3@FGPKFB>
Date: Fri, 10 Feb 2006 12:04:58 -0-800
From: "Chiasson" <maria2657@comcast.net>
Reply-To: "<maria2657@comcast.net>"
To: <freebsd-gnats-submit@freebsd.org>
Subject: February 9, 2006 Inf0rmati0n Update

>Number:         93142
>Category:       junk
>Synopsis:       February 9, 2006 Inf0rmati0n Update
>Confidential:   no
>Severity:       serious
>Priority:       medium
>Responsible:    gnats-admin
>State:          closed
>Quarter:        
>Keywords:       
>Date-Required:  
>Class:          sw-bug
>Submitter-Id:   current-users
>Arrival-Date:   Fri Feb 10 18:20:02 GMT 2006
>Closed-Date:    Fri Feb 10 22:08:57 GMT 2006
>Last-Modified:  Fri Feb 10 22:08:57 GMT 2006
>Originator:     
>Release:        
>Organization:
>Environment:
>Description:
 Dermisonics Develops Working Model of Antiseptic Wand In The
 $1.2 Billion Wound Care Market
 
 Now In Talks With U.S. Army to Build Battlefield Version
 
 Volume Jumps 75% Today
 _____________________________________________________________
 
 C0mpany: Dermisonics Inc.
 Sect0r; Conglomerates
 Symb. DMSI
 High: $0.49
 Vol. Up: 75%
 
 
 Is momentum to the upside building on this stock? Go
 Look at The Chart on it Right Now! Is there a Quick Trade
 in this Stock for You? watch it Trade Tomorrow. Radar it NOW!
 
 Check out their website and reveiw the full news release below. With an annoucement 
 like this in the market we are very excited to see where this stock goes moving forward.
 
 The News
 
 WEST CONSHOHOCKEN, Pa., Feb. 6 /CNW/ -- Dermisonics, Inc. (OTC Bulletin Board: DMSI.OB), 
 a pioneer in the development of ultrasonic transdermal drug-delivery technologies, 
 announced today that it has completed the first working model of its A-Wand antiseptic 
 delivery system and is in talks with the Army Institute of Surgical Research under the 
 Combat Casualty Care Research Program to develop a battlefield version.
 
 The A-Wand (TM) is a handheld, portable, ultrasonic wand device for applying antiseptic 
 solutions to cuts, abrasions and wounds with a replaceable Patch-Cap (TM), which holds 
 up to 40 ml of antiseptic solution. It uses alternating ultrasonic waveforms to enlarge 
 the diameter of the skin pores enabling antiseptics to permeate through the skin 
 (Stratum Corneum) into the dermis through the sweat pores.
 
 Attacks Critical Problem of Infections in Wounded Soldiers -- Infection is a major, 
 potentially lethal, battlefield hazard for wounded soldiers before they can receive 
 full medical treatment in a hospital. The Medic on the scene applies antiseptic and 
 bandages the wound but the antiseptic only affects the outermost layers of the damaged 
 tissue. Infection frequently results and is a major cause of amputations.
 
 The A-Wand Encapsulates the Wounded Area with Antiseptic -- The A-Wand would be used by 
 Medics in the field, by Mash units and for follow-up wound care to significantly reduce 
 this hazard. Through the use of the A-Wand's ultrasound system, the antiseptic solution 
 is "pushed" to the deeper tissue where it can more effectively fight infection by 
 surrounding and encapsulating the wounded area with antiseptic. It also has the added 
 advantage of being able to penetrate scared tissue without damaging this basic body 
 defense system.
 
 Technology inventor and Dermisonics Executive Vice-President Bruce Redding commented, 
 "The A-Wand represents a huge opportunity for Dermisonics and the various patients who 
 could benefit from increased infection-resistant technologies. Dermisonics especially 
 is pleased by the response from the US Army and we hope this technology finds acceptance 
 in the field as soon as possible"
 
 The Next Generation in the $1.2 Billion Wound Care Market -- The Company believes the 
 A-Wand will represent a significant shift in wound-care medical science and will 
 fundamentally change the $1.2 billion wound-care market.
 
 Industry Opportunity and Receptivity -- As a harbinger of its immediate industry impact, 
 the Company has already received, in addition to the military, strong indications of 
 interest from major companies in the pharmaceutical and hospital fields.
 
 Ab0ut: 
 
 Dermisonics is an intellectual property company and advanced technology
 incubator that is primarily focused on the ongoing development, testing and
 eventual commercialization of a transdermal patch that has been designed to
 facilitate the efficient and needle-free delivery of drugs with large
 molecular structures into the bloodstream. Its breakthrough system, called
 the U-Strip, is based on a radical integration of microelectronics and
 ultrasonic science with a product-carrying patch, and represents a quantum
 leap in non- invasive, transdermal delivery technology. Tests have shown
 that this system facilitates the transdermal delivery of insulin as well as
 potentially at least 175 other existing drugs that at present cannot be
 effectively delivered through the pores of the skin using conventionally
 available transdermal technology due to their large molecular size. The
 Company has also developed other portable ultrasonic systems for
 applications in the medical (Antiseptic Wand) and skin care (U-Wand) fields.
 
 ______________
 
 
 
 Information within this em  ail contains 4rward l0 0king statements within
 the meaning of Section 27A of the Secu rities Act of nineteen thirty three
 and Section 21B of the Securi ties Exch ange Act of nineteen thirty four. Any
 statements that express or involve discussions with respect to predi ctions,
 expec tations, beli efs, pla ns, projec tions, objec tives, goa ls, ass
 umptions or future events or performance are not statements of historical
 fact and may be 4rward 1o0king statements. Don't rely on them to make a
 decision. As with many micr ocap st0c ks, today's  com pany has disclosable material
 items you need to consider in order to make an informed and intelligent
 in_vest ment decision. These items include: a reliance on loans from
 offi cers, some related party transactions, a goin concern opinion from its
 auditor, no reven ues in its most recent quar ter, a large accumulated deficit,
 default on not es pay able that could cause the com pany to lose its intellectual
 property, and potential  litigation over its technology. It is not an operating comp any
 and is going to need fin ancing. Read the Company's S E C Fili ngs now, right now, before
 you inve st. None of the material within this report shall be construed as any kind of in
 vestment advi ce or solicitat ion. Many of these small compa nies are on the verge of
 bankr uptcy. You can lose all your m0ny by in-ves ting in this st0c k. In
 compliance with the Securi ties Act of 19 33, Sec tion 17(b),we disclose the receipt of
 four hundred twenty five thousand free trading shares received from a third party, not
 an officer, director or affiliate shareholder for our services. We intend to sell our
 stock now. This could cause the stock to go down, resulting in losses for you. All
 factual informa tion in this report was gathered from public sources, including but
 not limited to Comp any Pre ss Releas es and Fili ngs.
>How-To-Repeat:
>Fix:
>Release-Note:
>Audit-Trail:
State-Changed-From-To: open->closed 
State-Changed-By: linimon 
State-Changed-When: Fri Feb 10 22:08:19 UTC 2006 
State-Changed-Why:  
spam 

http://www.freebsd.org/cgi/query-pr.cgi?pr=93142 
>Unformatted:
